News
Size matters... and structure too!
CRG Researchers developed Global Score, a method that allows, for the first time, to predict protein interactions with long non-coding RNAs.
CaixaImpulse 2017 - New call for projects now open
Aimed at researchers in the fields of Healthcare and Life Sciences, interested in transferring research assets from the lab to society and the market.
Projects may be submitted from 1 February to 15 March 2017
MicrobioMx wins the S2B Concept Challenge
MicrobioMx, a project led by CRG researchers Toni Gabaldon and Pedro González, wins the Science to Business (S2B) Concept Challenge 2016.
New public-private initiative to develop a new therapy against aterosclerosis
The project - which has just received 700,000 euros in the Spanish 2016 Retos-Colaboracion call- is led by biotech Iproteos with the participation of the Biomedical Research Institute of Barcelona...
Local company Made of Genes in ‘El cazador de cerebros’
Saturday November 5th, Made of Genes was in the TV program ‘El cazador de cerebros - ¿Querrías saber tu destino genético?’ broadcasted by TVE La 2.
CRG Proof of Concept: Commercialization Gap Fund (CGF)
Deadline : 01/11/2016 (Last days to apply!)
Please send your Full Proposal (max. 10 pages) under the following schemes:
- MIDI - Up to 6 months and 35 kEUR
- MAXI - Up to 12 months and 75 kEUR
Science to Business (S2B) Concept Challenge
Deadline : 01/11/2016 (Last days to apply!)
Don't miss out on your opportunity to see your innovation go from conception to success. Send your application (max. 10 slides) addressing the following guidelines:
- About You 1 slide
- Technology 2–3 slides
- Potential Applications 1-2 slides
- Path to Market 1-2 slides
- Risks 1 slide
- Plan 1 slide
Dedos de Zinc, una posible solución a la enfermedad de Huntington (CRG / Diario Médico)
Dedos de Zinc, una posible solución a la enfermedad de Huntington (CRG / Diario Médico)Una inyección reduce la enfermedad de Huntington en ratones durante varios meses (CRG / La Vanguardia.com)
Una inyección reduce la enfermedad de Huntington en ratones durante varios meses (CRG / La Vanguardia.com)
Strengthening gene therapy for Huntington’s disease
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington’s disease for several months in a trial in mice.